Giulia Benevolo

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli et al. · Blood · 2010 · 382 citations · Full text

Medicine, Hematology, Pharmacology +14

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Antonio Palumbo, Sara Bringhen, Anna Marina Liberati et al. · Blood · 2008 · 357 citations · Full text

Medicine, Hematology, Oncology +15

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Francesco Passamonti, Toni Giorgino, Barbara Mora et al. · Leukemia · 2017 · 334 citations · Full text

Medicine, Hematology, Molecular Medicine +5